doi: 10.1002/osp4.70033, 28 DossatA
High Costs & Systemic Barriers Exacerbate Health Inequities Policy Reforms Are Critical to Address Structural Inequities High Costs and Systemic Barriers Exacerbate Health Inequities: The products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are priced at roughly $1,000 per month
Mounjaro is given at an initial dose of 2.5 mg and after four weeks, increased to 5 mg
Additionally, 111 In-labeled [Lys 40 (Ahx-DTPA- 111 In)NH 2 ]-exendin-4 has demonstrated potent tumor accumulation and cytotoxicity in the Rip1Tag2 mouse model, reducing tumor volume by up to 94% following a single dose without off-target toxicity [351, 352]
Its the early testing edge that has Regeneron excited about Hansohs HS-20094, since the drug has already been studied in over 1k patients, leading Regeneron to claim it has a potentially similar profile to Lillys popular GLP-1/GIP agonist